• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine admi

tetano

Editor, Senior Moderator
Hum Vaccin Immunother. 2018 Feb 9:0. doi: 10.1080/21645515.2018.1438791. [Epub ahead of print]
[h=1]IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.[/h] Terauchi Y[SUP]1,[/SUP][SUP]2[/SUP], Sano K[SUP]1[/SUP], Ainai A[SUP]1[/SUP], Saito S[SUP]3[/SUP], Taga Y[SUP]4[/SUP], Ogawa-Goto K[SUP]4[/SUP], Tamura SI[SUP]1[/SUP], Odagiri T[SUP]3[/SUP], Tashiro M[SUP]3[/SUP], Fujieda M[SUP]2[/SUP], Suzuki T[SUP]1[/SUP], Hasegawa H[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Unlike the current injectable influenza vaccines, intranasally administered influenza vaccines induce influenza virus-specific IgA antibodies in the local respiratory mucosa as well as IgG antibodies in the systemic circulation. Our previous study showed that after five volunteers underwent intranasal administration with inactivated H3N2 or H5N1 vaccines, their IgA antibodies on the upper respiratory tract were present as monomers, dimers, and multimers (trimers and tetramers). Moreover, the multimers associated with the highest virus neutralizing activity. However, it has remained elusive whether a more practical intranasal vaccination strategy could induce the high-performance IgA multimers in the nasal mucosa. In the present study, volunteers were administered with two doses of the intranasal trivalent whole-virus inactivated influenza vaccine and showed that in nasal wash samples the amount of multimeric IgA correlated positively with virus neutralizing titers, indicating that the multimeric IgA antibodies play an important role in the antiviral activity at the nasal mucosa. Surface plasmon resonance analysis of the binding dynamics of nasal wash derived IgA monomers, dimers, and multimers against recombinant trimeric influenza virus HA showed that sample fractions containing IgA multimers dissociated from HA less well than sample fractions without IgA multimers. Thus, IgA multimers may "stick" to the antigen more tightly than the other structures. In summary, intranasal administration of two doses of multivalent inactivated influenza vaccines induced multimeric IgA. Multimerization of mucosal IgA antibodies conferred higher neutralizing activity against viruses in the nasal mucosa, possibly by increasing their cohesion to virus antigens. (243 words Limit: 250 words).


[h=4]KEYWORDS:[/h] Secretory IgA antibody; influenza virus; intranasal inactivated influenza vaccine; multimeric SIgA antibody; upper respiratory mucosa

PMID: 29425074 DOI: 10.1080/21645515.2018.1438791
 
Back
Top Bottom